We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+6.08%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$42.8B
AUM Growth
+$3.35B
(+8.5%)
Cap. Flow
+$1.35B
Cap. Flow
% of AUM
3.15%
Top 10 Holdings %
Top 10 Hldgs %
14.82%
Holding
2,894
New
39
Increased
2,631
Reduced
168
Closed
44
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$21.8M |
| 2 |
Chevron
CVX
|
+$20.5M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$19.7M |
| 4 |
Incyte
INCY
|
+$17.8M |
| 5 |
ExxonMobil
XOM
|
+$16.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SE
Spectra Energy Corp Wi
SE
|
+$49.6M |
| 2 |
STJ
St Jude Medical
STJ
|
+$41.1M |
| 3 |
LLTC
Linear Technology Corp
LLTC
|
+$30.3M |
| 4 |
HAR
Harman International Industries
HAR
|
+$13.8M |
| 5 |
ENH
Endurance Specialty Holdings Ltd
ENH
|
+$10.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 16.2% |
| 2 | Technology | 15.06% |
| 3 | Healthcare | 13.05% |
| 4 | Industrials | 10.88% |
| 5 | Consumer Discretionary | 9.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
851
Home BancShares
HOMB
$6.25B
| $6.6M | 0.02% |
243,763
+71,077
| +41% | +$1.95M |
|
852
Avient
AVNT
$3.36B
| $6.58M | 0.02% |
193,134
+6,917
| +4% | +$232K |
|
|
IDTI
853
DELISTED
Integrated Device Technology I
IDTI
| $6.52M | 0.02% |
275,485
+7,664
| +3% | +$188K |
|
854
Evercore
EVR
$12.1B
| $6.49M | 0.02% |
83,368
+23,320
| +39% | +$1.81M |
|
855
Kennametal
KMT
$2.54B
| $6.49M | 0.02% |
165,332
+5,266
| +3% | +$194K |
|
856
CACI
CACI
$10.5B
| $6.48M | 0.02% |
55,278
+13,288
| +32% | +$1.65M |
|
|
PPLI
857
People Inc
PPLI
$3.08B
| $6.48M | 0.02% |
491,585
+23,065
| +5% | +$300K |
|
858
Sanmina
SANM
$9.83B
| $6.47M | 0.02% |
159,322
+41,372
| +35% | +$1.6M |
|
859
Arista Networks
ANET
$215B
| $6.45M | 0.02% |
780,032
+94,384
| +14% | +$651K |
|
860
Ionis Pharmaceuticals
IONS
$8.81B
| $6.44M | 0.02% |
160,198
+5,738
| +4% | +$258K |
|
|
TMX
861
DELISTED
Terminix Global Holdings, Inc.
TMX
| $6.44M | 0.02% |
230,174
+13,852
| +6% | +$360K |
|
862
Timken Company
TKR
$9.46B
| $6.42M | 0.02% |
142,027
+6,187
| +5% | +$273K |
|
|
MDSO
863
DELISTED
Medidata Solutions, Inc.
MDSO
| $6.41M | 0.02% |
111,066
+31,662
| +40% | +$1.71M |
|
|
WNR
864
DELISTED
Western Refining Inc
WNR
| $6.38M | 0.01% |
182,014
+7,178
| +4% | +$259K |
|
865
Minerals Technologies
MTX
$2.25B
| $6.34M | 0.01% |
82,769
+2,160
| +3% | +$167K |
|
866
Valley National Bancorp
VLY
$7.92B
| $6.34M | 0.01% |
536,936
+24,491
| +5% | +$294K |
|
867
O-I Glass
OI
$1.13B
| $6.31M | 0.01% |
309,663
+15,236
| +5% | +$298K |
|
868
Lazard
LAZ
$4.09B
| $6.31M | 0.01% |
137,214
+10,064
| +8% | +$434K |
|
869
Oceaneering
OII
$4.74B
| $6.31M | 0.01% |
232,878
-102,860
| -31% | -$2.81M |
|
870
Prestige Consumer Healthcare
PBH
$2.37B
| $6.31M | 0.01% |
113,504
+3,849
| +4% | +$212K |
|
|
AZPN
871
DELISTED
ASPEN TECHNOLOGY INC
AZPN
| $6.3M | 0.01% |
106,972
+2,932
| +3% | +$173K |
|
|
PE
872
DELISTED
PARSLEY ENERGY INC
PE
| $6.3M | 0.01% |
193,826
+36,843
| +23% | +$1.22M |
|
873
Spire
SR
$4.76B
| $6.3M | 0.01% |
93,327
+24,361
| +35% | +$1.59M |
|
|
HPP
874
Hudson Pacific Properties
HPP
$766M
| $6.3M | 0.01% |
25,964
+5,103
| +24% | +$1.26M |
|
875
CNX Resources
CNX
$4.9B
| $6.29M | 0.01% |
450,103
-11,303
| -2% | -$159K |
|
Similar funds
VAM
RhumbLine Advisers's Q1 2017 Portfolio in Review
As of Q1 2017, RhumbLine Advisers held 2,894 positions worth $42.8B, up 8.5% from $39.5B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
RhumbLine Advisers deployed $1.35B of net new capital in Q1 2017, opening 39 new positions and adding to 2,631 existing holdings. Its largest new stake was Bioverativ Inc. Common Stock: 197,812 shares worth $10.8M.
By sector, the portfolio is most concentrated in Financials at 16% of assets, down from 17% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Biogen, an estimated $8.21M trimmed.
- RhumbLine Advisers's largest Q1 2017 buy was Bioverativ Inc. Common Stock: 197,812 shares worth $10.8M.
- RhumbLine Advisers added most to Abbott in Q1 2017, an estimated $21.8M increase.
- RhumbLine Advisers's biggest Q1 2017 reduction was Biogen, cutting an estimated $8.21M.
- RhumbLine Advisers fully exited Spectra Energy Corp Wi in Q1 2017, selling an estimated $49.6M.
- RhumbLine Advisers's ten largest holdings make up 15% of its $42.8B portfolio in Q1 2017.
- RhumbLine Advisers opened 39 new positions and closed 44 in Q1 2017.
- RhumbLine Advisers's portfolio value rose 8.5% quarter-over-quarter to $42.8B.
Based on RhumbLine Advisers's 13F filing for Q1 2017, filed 2 May 2017.